Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab

Journal of Microscopy

Volumn 254, Issue 1, 2014, Pages 19-30

  Li, M ^a,b   Xiao, X ^c   Zhang, W ^c   Liu, L ^a   Xi, N ^a,d   Wang, Y ^a  

^a SHENYANG INSTITUTE OF AUTOMATION   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atomic force microscopy; CD20; Lymphoma; Rituximab; ROR1; Single molecule force spectroscopy

Indexed keywords

ATOMIC FORCE MICROSCOPY; BINDING ENERGY; BONE; CELL MEMBRANES; CYTOLOGY; MOLECULES; MONOCLONAL ANTIBODIES; NANOTECHNOLOGY; ONCOLOGY;

ATOMIC-FORCE-MICROSCOPY; B CELLS; B-CELL LYMPHOMA; CD20; LYMPHOMA; NANOSCALE DISTRIBUTION; RITUXIMAB; ROR1; SINGLE MOLECULE FORCE SPECTROSCOPY; TUMOUR CELLS;

TUMORS;

BIOLOGICAL MARKER; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MACROGOL; PREDNISONE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; ATOMIC FORCE MICROSCOPY; B CELL LYMPHOMA; BINDING AFFINITY; BONE MARROW CELL; CASE REPORT; CELLULAR DISTRIBUTION; DRUG EFFICACY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINGLE MOLECULE FORCE SPECTROSCOPY; SPECTROSCOPY; SPLENIC MARGINAL ZONE LYMPHOMA; THERAPY EFFECT;

ATOMIC FORCE MICROSCOPY; CD20; LYMPHOMA; RITUXIMAB; ROR1; SINGLE-MOLECULE FORCE SPECTROSCOPY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; LYMPHOMA, B-CELL; MICROSCOPY, ATOMIC FORCE; PROTEIN BINDING;

EID: 84896874041     PISSN: 00222720     EISSN: 13652818     Source Type: Journal    
DOI: 10.1111/jmi.12112     Document Type: Article

References (55)

1. Alduaij, W. & Illidge, T.M. (2011) The future of anti-CD20 monoclonal antibodies: are we making progress. Blood 117, 2993-3001.
2. Altschuler, S.J. & Wu, L.F. (2010) Cellular heterogeneity: do differences make a difference? Cell 141, 559-563.
3. Ando, T. (2012) High-speed atomic force microscopy coming of age. Nanotechnology 23, 062001.
4. Barna, G., Mihalik, R., Timar, B. et al. (2011) ROR1 expression is not a unique marker of CLL. Hematol. Oncol. 29, 17-21.
5. Baskar, S., Wiestner, A., Wilson, W.H., Pastan, I. & Rader, C. (2012) Targeting malignant B cells with an immunotoxin against ROR1. mAbs. 4, 349-361.
6. Bedard, P.L., Hansen, A. R., Ratain, M.J & Siu, L.L. (2013) Tumour heterogeneity in the clinic. Nature 501, 355-364.
7. Beers, S.A., Chan, C.H.T., French, R.R., Cragg, M.S. & Glennie, M.J. (2010) CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47, 107-114.
8. Binnig, G., Quate, C.F. & Gerber, C. (1986) Atomic force microscope. Phys. Rev. Lett. 56, 930-933.
9. Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019-5032.
10. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635-2642.
11. Carvalho, F.A. & Santos, N.C. (2012) Atomic force microscopy-based force spectroscopy-biological and biomedical applications. IUBMB Life 64, 465-472.
12. Cheson, B.D & Leonard, J.P. (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359, 613-626.
13. Derda, R., Laromaine, A., Mammoto, A., Tang, S.K.Y., Mammoto, T., Ingber, D.E. & Whitesides, G.M. (2009) Paper-supported 3D cell culture for tissue-based bioassays. Proc. Natl. Acad. Sci. USA 106, 18457-18462.
14. Dufrene, Y.F., Evans, E., Engel, A., Helenius, J., Gaub, H.E. & Muller, D.J. (2011) Five challenges to bringing single-molecule force spectroscopy into living cells. Nat. Methods 8, 123-127.
15. Dupres, V., Menozzi, F.D., Locht, C. et al. (2005) Nanoscale mapping and functional analysis of individual adhesions on living bacteria. Nat. Methods 2, 515-520.
16. El-Kirat-Chatel, S. & Dufrene, Y.F. (2012) Nanoscale imaging of the candida-macrophage interaction using correlated fluorescence-atomic force microscopy. ACS Nano 6, 10792-10799.
17. Glennie, M.J., French, R.R., Crag, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823-3837.
18. Hamburg, M.A. & Collins, F.S. (2010) The path to personalized medicine. N. Engl. J. Med. 363, 301-304.
19. Hanahan, D. & Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
20. Hecht, E., Thompson, K., Frick, M., Wittekindt, O.H., Dietl, P., Mizaikoff, B. & Kranz, C. (2012) Combined atomic force microscopy-fluorescence microscopy: analyzing exocytosis in alveolar type II cells. Anal. Chem. 84, 5716-5722.
21. Hinterdorfer, P. & Dufrene, Y.F. (2006) Detection and localization of single molecular recognition events using atomic force microscopy. Nat. Methods 3, 347-355.
22. Huh, Y.O., Keating, M.J., Saffer, H.L., Jilani, I., Lerner, S. & Albitar, M. (2001) Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 116, 437-443.
23. Hutter, J.L. & Bechhoefer, J. (1993) Calibration of atomic-force microscope tips. Rev. Sci. Instrum. 64, 1868-1873.
24. Junttila, M.R. & Sauvage, F.J.D. (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354.
25. Kenakin, T. (2004) Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25, 186-192.
26. Kirmse, R., Otto, H. & Ludwig, T. (2011) Interdependency of cell adhesion, force generation and extracellular proteolysis in matrix remodeling. J. Cell Sci. 124, 1857-1866.
27. Kuppers, R. (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5, 251-262.
28. Leandro, M.J. (2013) B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res. Ther. 15, S3.
29. Li, B., Zhao, L., Guo, H. et al. (2009) Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 114, 5007-5015.
30. Li, M., Xiao, X., Liu, L., Xi, N., Wang, Y., Dong, Z. & Zhang, W.J. (2013a) Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition. J. Mol. Recognit. 26, 432-438.
31. Li, M., Xiao, X., Liu, L., Xi, N., Wang, Y., Dong, Z. & Zhang, W.J. (2013b) Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients. Exp. Cell Res. 319, 2812-2821.
32. Li, M., Liu, L.Q., Xi, N., Wang, Y., Dong, Z., Xiao, X. & Zhang, W. (2013c) Atomic force microscopy imaging of live mammalian cells. Sci. China Life Sci. 56, 811-817.
33. Maloney, D.G. (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366, 2008-2016.
34. Marte, B. (2013) Tumour heterogeneity. Nature 501, 327.
35. Molina, A. (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Ann. Rev. Med. 59, 237-250.
36. Morin, R.D., Mendez-Lago, M., Mungall, A.J. et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303.
37. Muller, D.J., Helenius, J., Alsteens, D. & Dufrene, Y.F. (2009) Force probing surfaces of living cells to molecular resolution. Nat. Chem. Biol. 5, 383-390.
38. Nagrath, S., Sequist, L.V., Maheswaran, S. et al. (2007) Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature 450, 1235-1239.
39. Oddershede, L.B. (2012) Force probing of individual molecules inside the living cell is now a reality. Nat. Chem. Biol. 8, 879-886.
40. Parton, R.G. & Simons, K. (2007) The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8, 185-194.
41. Pelkmans, L. (2012) Using cell-to-cell variability - a new era in molecular biology. Science 336, 425-426.
42. Perz, J., Topaly, J., Fruehauf, S. Hensel, M. & Ho, A.D. (2002) Level of CD20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 43, 149-151.
43. Rebagay, G., Yan, S., Liu, C. & Cheung, N.K. (2012) ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front. Oncol. 2, 34.
44. Rezvani, A.R. & Manoney, D.G. (2011) Rituximab resistance. Best Pract. Res. Clin. Haematol. 24, 203-216.
45. Sehn, L.H., Scott, D.W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., Connors, J.M. & Gascoyne, R.D. (2011) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 29, 1452-1457.
46. Shankland, K.R., Armitage, J.O. & Hancock, B.W. (2012) Non-Hodgkin lymphoma. Lancet 380, 848-857.
47. Snijder, B., Sacher, R., Ramo, P. et al. (2012) Single-cell analysis of population context advances RNAi screening at multiple levels. Mol. Syst. Biol. 8, 579.
48. Stephenson, R.P. (1956) A modification of receptor theory. Brit. J. Pharmacol. 11, 379-393.
49. Stroh, C., Wang, H., Bash, R. et al. (2004) Single-molecule recognition imaging microscopy. Proc. Natl. Acad. Sci. USA 101, 12503-12507.
50. Suzuki, A., Sekiya, S., Onishi, M., Oshima, N., Kiyonari, H., Nakauchi, H. & Taniquchi, H. (2008) Flow cytometric isolation and clonal identification of self-renewing bipotent hepatic progenitor cells in adult mouse liver. Hepatology 48, 1964-1978.
51. Tsirigotis, P. & Economopoulos, T. (2008) Monoclonal antibodies in the treatment of lymphoid malignancies. J. Steroid Biochem. Mol. Biol. 108, 267-271.
52. Uhrmacher, S., Schmidt, C., Erdfelder, F., Poll-Wolbeck, S.J., Gehrke, I., Hallek, M. & Kreuzer, K.A. (2011) Use of the receptor tyrosine kinase-like orphan receptor (ROR1) as a diagnostic tool in chronic lymphocytic leukemia(CLL). Leuk. Res. 35, 1360-1366.
53. van Meerten, T., van Rijn, R.S., Hol, S., Hagenbeek, A. & Ebeling, S.B. (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12, 4027-4035.
54. Weiner, G.J. (2010) Rituximab: mechanism of action. Semin. Hematol. 47, 115-123.
55. Zhang, S., Chen, L., Wang-Rodriguez, J., Zhang, L., Cui, B., Frankel, W., Wu, R. & Kipps, T.J. (2012) The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903-1910.